+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chemotherapy Induced Neutropenia Market - Global Forecast 2026-2032- Product Image
Chemotherapy Induced Neutropenia Market - Global Forecast 2026-2032- Product Image
New

Chemotherapy Induced Neutropenia Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 196 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6011313
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The chemotherapy induced neutropenia market is evolving rapidly, driven by advances in biologics, care delivery models, and shifting regulatory landscapes. Senior decision-makers face an environment characterized by increasing complexity, where clinical, operational, and commercial priorities intersect to shape access, adoption, and strategic planning.

Market Snapshot: Chemotherapy Induced Neutropenia Market

The chemotherapy induced neutropenia market grew from USD 1.61 billion in 2025 to USD 1.68 billion in 2026. The market is projected to continue expanding at a CAGR of 5.55%, reaching USD 2.35 billion by 2032.

Scope & Segmentation

  • Product Types: Includes Eflapegrastim, Filgrastim, Lipegfilgrastim, and Pegfilgrastim, each with distinct pharmacokinetic and administration profiles.
  • Therapy Segmentation: Differentiates between prophylactic and treatment approaches, informing clinical strategies and utilization patterns.
  • Route of Administration: Covers intravenous and subcutaneous formulations, supporting both inpatient and home-based care settings.
  • End User Environments: Spans clinics, home care, and hospitals, with operational capabilities and care delivery models affecting product choice.
  • Distribution Channel Dynamics: Includes hospital pharmacy, online pharmacy, and retail pharmacy pathways, each with specific logistics and reimbursement interactions.
  • Treatment Settings: Considers differences between inpatient and outpatient administration, impacting dosing schedules and integration of supportive measures.
  • Patient Populations: Addresses unique needs across adult, geriatric, and pediatric groups requiring tailored monitoring and education.
  • Dosage Strengths: Encompasses prescribing and inventory strategies for 5 Mcg/Kg and 6 Mg formulations.
  • Regions: Examines adoption and procurement trends in the Americas, Europe, Middle East & Africa, and Asia‑Pacific.
  • Technologies: Analyzes the impact of long-acting biologics, biosimilars, digital health tools, and device innovation on care delivery and patient outcomes.

Key Takeaways for Senior Leaders

  • Modern neutropenia management integrates novel long‑acting agents and biosimilars, redefining treatment pathways and intensifying market competition.
  • Shift toward outpatient and home administration is transforming logistics, supported by digital tools and patient education to minimize unnecessary clinic visits.
  • Stakeholders are adapting procurement and contracting strategies, aiming for supply resilience and alignment with evolving reimbursement models.
  • Clinical guidelines increasingly incorporate real-world evidence and risk stratification, enabling more personalized prophylaxis and therapy choices.
  • Operational priorities now include investment in cold chain logistics and remote monitoring for early intervention and streamlined administration.
  • Effective alignment between manufacturers, providers, and payers supports continuity in care while navigating policy and supply chain pressures.

Tariff Impact on Supply Chain & Procurement

In the United States, 2025 tariff measures added new complexity to supportive oncology supply chains. Manufacturers and distributors restructured sourcing and accelerated nearshoring to manage increased costs and mitigate supply disruptions. Procurement contracts now favor multi-year terms and flexible volume protections to enhance continuity and predictability across geographically distributed manufacturing networks. Hospitals, payers, and clinicians are prioritizing therapeutic continuity and tariff-sensitive supply resilience, shaping commercial strategies across all stakeholder groups.

Methodology & Data Sources

This research employed mixed methods, including expert interviews with key opinion leaders, oncology pharmacists, and procurement specialists, alongside an extensive review of clinical literature, regulatory documents, and professional society guidance. Triangulation techniques and validation from multiple independent sources ensure actionable and reproducible findings for decision-makers.

Why This Report Matters

  • Enables organizations to navigate operational and commercial complexities in neutropenia therapy adoption and supply chain management.
  • Delivers strategic insights for aligning clinical protocols, procurement planning, and stakeholder engagement in a rapidly evolving market.
  • Supports evidence-based decision-making to optimize patient outcomes and resource allocation across regional and care-delivery contexts.

Conclusion

As the chemotherapy induced neutropenia market evolves, senior stakeholders must respond with integrated, data-driven strategies. Coordinated actions across the value chain will be essential for improving patient access, operational resilience, and clinical outcomes in a challenging market landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Chemotherapy Induced Neutropenia Market, by Product Type
8.1. Eflapegrastim
8.2. Filgrastim
8.3. Lipegfilgrastim
8.4. Pegfilgrastim
9. Chemotherapy Induced Neutropenia Market, by Therapy
9.1. Prophylaxis
9.2. Treatment
10. Chemotherapy Induced Neutropenia Market, by Route Of Administration
10.1. Intravenous Injection
10.2. Subcutaneous Injection
11. Chemotherapy Induced Neutropenia Market, by Treatment Setting
11.1. Inpatient
11.2. Outpatient
12. Chemotherapy Induced Neutropenia Market, by Distribution Channel
12.1. Online
12.2. Offline
13. Chemotherapy Induced Neutropenia Market, by End User
13.1. Clinic
13.2. Home Care
13.3. Hospital
14. Chemotherapy Induced Neutropenia Market, by Patient Group
14.1. Adult
14.2. Geriatric
14.3. Pediatric
15. Chemotherapy Induced Neutropenia Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Chemotherapy Induced Neutropenia Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Chemotherapy Induced Neutropenia Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Chemotherapy Induced Neutropenia Market
19. China Chemotherapy Induced Neutropenia Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. Amgen Inc.
20.6. AstraZeneca plc
20.7. Aurobindo Pharma Limited
20.8. BeyondSpring Pharmaceuticals Inc.
20.9. Biocon Biologics India Limited
20.10. Celltrion Healthcare Co., Ltd.
20.11. Coherus BioSciences Inc.
20.12. Dr. Reddy's Laboratories Ltd.
20.13. Evive Biotech
20.14. Fresenius Kabi AG
20.15. G1 Therapeutics, Inc.
20.16. GlaxoSmithKline plc
20.17. Hanmi Pharmaceutical Co., Ltd.
20.18. Intas Pharmaceuticals Ltd.
20.19. Kyowa Kirin Co., Ltd.
20.20. Lupin Limited
20.21. Merck & Co., Inc.
20.22. Mundipharma International Limited
20.23. Novartis AG
20.24. Pfizer Inc.
20.25. Roche Holding AG
20.26. Spectrum Pharmaceuticals, Inc.
20.27. Teva Pharmaceutical Industries Ltd.
20.28. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY EFLAPEGRASTIM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LIPEGFILGRASTIM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 74. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 96. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 98. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 99. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 101. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 112. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 114. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 115. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 116. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 117. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 129. ASEAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 130. ASEAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 131. ASEAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 132. ASEAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. ASEAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 134. ASEAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135. ASEAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. ASEAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 137. GCC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. GCC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 139. GCC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 140. GCC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 141. GCC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 142. GCC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 143. GCC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. GCC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 153. BRICS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 154. BRICS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 155. BRICS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 156. BRICS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 157. BRICS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 158. BRICS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. BRICS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. BRICS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 161. G7 CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. G7 CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 163. G7 CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 164. G7 CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. G7 CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 166. G7 CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. G7 CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. G7 CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 169. NATO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. NATO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 171. NATO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 172. NATO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 173. NATO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 174. NATO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 175. NATO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. NATO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 177. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 178. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 179. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 180. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 182. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 183. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 184. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
TABLE 186. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 187. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 188. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY THERAPY, 2018-2032 (USD MILLION)
TABLE 189. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 190. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
TABLE 191. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Chemotherapy Induced Neutropenia market report include:
  • Amgen Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • BeyondSpring Pharmaceuticals Inc.
  • Biocon Biologics India Limited
  • Celltrion Healthcare Co., Ltd.
  • Coherus BioSciences Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Evive Biotech
  • Fresenius Kabi AG
  • G1 Therapeutics, Inc.
  • GlaxoSmithKline plc
  • Hanmi Pharmaceutical Co., Ltd.
  • Intas Pharmaceuticals Ltd.
  • Kyowa Kirin Co., Ltd.
  • Lupin Limited
  • Merck & Co., Inc.
  • Mundipharma International Limited
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Spectrum Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.68 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.35 Billion
Compound Annual Growth Rate5.5%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Chemotherapy-induced Neutropenia Treatment Market Size, Share & Trends Analysis Report By Treatment (Growth Factors, Antibiotics), By Drug, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 195 Pages
  • Global
From
Chemotherapy-induced Neutropenia Therapeutics Market Outlook 2026-2034: Market Share, and Growth Analysis - Product Image

Chemotherapy-induced Neutropenia Therapeutics Market Outlook 2026-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025 - Product Image

Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • 40 Pages
  • Global
From
Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report - Product Image

Chemotherapy-Induced Neutropenia Treatment - Global Strategic Business Report

  • Report
  • 381 Pages
  • Global
From
Chemotherapy Induced Neutropenia - Pipeline Insight, 2025 - Product Image

Chemotherapy Induced Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Market

In the context of healthcare services, the chemotherapy-induced neutropenia (CIN) market encompasses the range of medical treatments, products, and services used to prevent and manage neutropenia, a common side effect of chemotherapy where a patient's neutrophil count becomes abnormally low, increasing the risk of infection. The market includes pharmaceuticals such as colony-stimulating factors (CSFs), which stimulate the bone marrow to produce more white blood cells, antibiotics for the prevention and treatment of infections, and diagnostic services that monitor neutrophil counts and infection markers. Healthcare service providers such as hospitals, specialty clinics, and oncology centers play a crucial role in administering these treatments and monitoring patient health outcomes. Research and development efforts in this market aim to deliver more efficacious and safer therapies, with a focus on personalized medicine approaches that tailor treatment to individual patient needs and genetic profiles. Companies operating within the CIN market span a variety of pharmaceutical manufacturers and biotechnology firms. Some notable players include Amgen, which produces Neupogen and Neulasta, drugs that are commonly used to treat neutropenia, and Pfizer, which offers a biosimilar to Neulasta called Nivestym. Other companies involved in the production of treatments for CIN include Teva Pharmaceutical Industries, Novartis, and Mylan, which offer generic and biosimilar versions of CSFs and supportive care medications essential for managing neutropenia in chemotherapy patients. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.